The end for genital human papillomavirus infections?
- 1 May 2005
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (5) , 256-257
- https://doi.org/10.1016/s1470-2045(05)70141-8
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Human papillomavirus (HPV) vaccines: prospects for eradicating cervical cancerBMJ Sexual & Reproductive Health, 2004
- Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of CausalityJNCI Monographs, 2003
- Chapter 16: Prophylactic Human Papillomavirus VaccinesJNCI Monographs, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groupsJournal of General Virology, 1996